|1.||Smith, Patrick: 1 article (04/2012)|
|2.||Perelson, Alan S: 1 article (04/2012)|
|3.||Guedj, Jeremie: 1 article (04/2012)|
|4.||Shudo, Emi: 1 article (04/2012)|
|5.||Dahari, Harel: 1 article (04/2012)|
|6.||Liu, Yanzhou: 1 article (11/2010)|
|7.||Li, Fujun: 1 article (11/2010)|
|8.||Lin, Fangling: 1 article (11/2010)|
|9.||Brandl, Michael: 1 article (11/2010)|
|10.||Chow, Justin: 1 article (11/2010)|
10/30/2010 - "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial."
08/01/2010 - "A phase Ib, 'IFN-free' clinical trial demonstrated that danoprevir, combined with the HCV polymerase inhibitor RG-7128 (Pharmasset Inc/Roche Holding AG), was effective in reducing HCV-RNA levels in a large proportion of treatment-naïve patients with HCV infection and in approximately half of previously non-responsive patients with HCV-1 infection, without resistance or safety concerns. "
11/02/2010 - "RG7128 is a di-ester prodrug of a cytidine analog for the treatment of hepatitis C virus (HCV) infection. "
|2.||Chronic Hepatitis C
|1.||RNA (Ribonucleic Acid)